Eiji Shinozaki

List of Publications by Year
in descending order

105	1,607	361413	345221
papers	citations	20 h-index	36 g-index

114	114	114	2495
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncology, The, 2017, 18, 1172-1181.	10.7	111
2	Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Science, 2019, 110, 1148-1155.	3.9	106
3	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer, 2016, 19, 183-191.	5.3	95
4	Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. Journal of Gastroenterology, 2018, 53, 1186-1195.	5.1	67
5	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Scientific Reports, 2019, 9, 17358.	3.3	67
6	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Medicine, 2019, 8, 408-417.	2.8	63
7	Immunotherapy in Colorectal Cancer: Current and Future Strategies. Journal of the Anus, Rectum and Colon, 2021, 5, 11-24.	1.1	59
8	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. British Journal of Cancer, 2017, 117, 1450-1458.	6.4	52
9	Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience. Japanese Journal of Clinical Oncology, 2008, 38, 426-431.	1.3	47
10	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemotherapy and Pharmacology, 2020, 85, 265-272.	2.3	47
11	Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Design, Development and Therapy, 2015, 9, 3099.	4.3	45
12	Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer, 2019, 22, 518-525.	5.3	44
13	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	7.0	44
14	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 34811-34823.	1.8	43
15	Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit. BMC Cancer, 2013, 13, 405.	2.6	42
16	RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. International Journal of Cancer, 2016, 139, 803-811.	5.1	38
17	Enrichment of CLDN18â€ARHGAP fusion gene in gastric cancers in young adults. Cancer Science, 2019, 110, 1352-1363.	3.9	38
18	Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Annals of Surgical Oncology, 2019, 26, 2507-2513.	1.5	32

#	Article	IF	Citations
19	Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer, 2018, 18, 406.	2.6	29
20	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100535.	3.0	29
21	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clinical Cancer Research, 2021, 27, 5619-5627.	7.0	27
22	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	3.7	23
23	Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer, 2017, 17, 38.	2.6	21
24	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. Annals of Surgical Oncology, 2020, 27, 3307-3315.	1.5	20
25	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer, 2021, 21, 674.	2.6	19
26	An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).. Journal of Clinical Oncology, 2015, 33, 3544-3544.	1.6	19
27	Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients. OncoTargets and Therapy, 2015, 8, 3329.	2.0	17
28	Nonâ€V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. International Journal of Cancer, 2019, 145, 2488-2495.	5.1	17
29	Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and Clinical Oncology, 2015, 3, 1053-1057.	1.0	15
30	Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. World Journal of Surgical Oncology, 2019, 17, 100.	1.9	15
31	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. Cancers, 2020, 12, 1566.	3.7	15
32	A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. International Journal of Clinical Oncology, 2018, 23, 92-97.	2.2	13
33	Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. Gastric Cancer, 2018, 21, 267-275.	5.3	12
34	Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.. Journal of Clinical Oncology, 2022, 40, 3518-3518.	1.6	11
35	Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). OncoTargets and Therapy, 2015, 8, 1111.	2.0	10
36	Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget, 2018, 9, 15219-15227.	1.8	10

#	Article	IF	Citations
37	Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. OncoTargets and Therapy, 2018, Volume 11, 8301-8307.	2.0	10
38	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical Colorectal Cancer, 2018, 17, e719-e732.	2.3	10
39	Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as secondâ€line chemotherapy. Cancer Medicine, 2021, 10, 615-625.	2.8	10
40	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 3530-3530.	1.6	10
41	Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer. Cancer Medicine, 2021, 10, 8820-8828.	2.8	10
42	Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. International Journal of Clinical Oncology, 2017, 22, 1060-1068.	2.2	9
43	Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 307-313.	2.3	9
44	Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemotherapy and Pharmacology, 2021, 87, 767-777.	2.3	8
45	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	3.0	8
46	Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. OncoTargets and Therapy, 2015, 8, 529.	2.0	7
47	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Design, Development and Therapy, 2015, 9, 1653.	4.3	7
48	Phase II trial of biweekly cetuximab and irinotecan as thirdâ€line therapy for pretreated KRAS exon 2 wildâ€type colorectal cancer. Cancer Science, 2018, 109, 2567-2575.	3.9	7
49	Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. PLoS ONE, 2021, 16, e0246160.	2.5	7
50	Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. Oncology Letters, 2021, 22, 783.	1.8	7
51	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Investigational New Drugs, 2020, 38, 111-119.	2.6	6
52	A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6â€‰+â€‰Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		6
53	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. International Journal of Clinical Oncology, 2021, 26, 335-344.	2.2	6
54	A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage â…¡/â…¢ Colon Cancer â€“ACTOR Studyâ€“. Anticancer Research, 2018, 38, 1741-1747.	1.1	6

#	Article	IF	Citations
55	Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018. Oncologist, 2022, 27, e506-e517.	3.7	6
56	Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf multicentre, randomised phase II trial (NOMINATE trial). BMJ Open, 2022, 12, e055140.	1.9	6
57	KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1273-1283.	2.5	6
58	Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. Cancer Management and Research, 2018, Volume 10, 5283-5290.	1.9	5
59	Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).. Journal of Clinical Oncology, 2016, 34, 3557-3557.	1.6	5
60	Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?. BMC Cancer, 2015, 15, 760.	2.6	4
61	Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer. Gastric Cancer, 2016, 19, 625-630.	5.3	4
62	Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab. Case Reports in Oncology, 2018, 11, 601-608.	0.7	4
63	Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study . Cancer Management and Research, 2019, Volume 11, 5757-5764.	1.9	4
64	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for nextâ€generation sequencing. Biomedical Reports, 2019, 11, 171-180.	2.0	4
65	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. BMC Cancer, 2020, 20, 358.	2.6	4
66	Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. Anticancer Research, 2021, 41, 3905-3915.	1.1	4
67	Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2014, 32, 3597-3597.	1.6	4
68	Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines.. Journal of Clinical Oncology, 2017, 35, 741-741.	1.6	4
69	Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab. OncoTargets and Therapy, 2015, 8, 2005.	2.0	3
70	Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 486-486.	1.6	3
71	Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer. PLoS ONE, 2017, 12, e0176745.	2.5	3
72	Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer. Advances in Therapy, 2022, , 1.	2.9	3

#	Article	IF	Citations
73	Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study. Journal of Gastrointestinal Cancer, 2023, 54, 475-484.	1.3	3
74	Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. International Journal of Colorectal Disease, 2022, 37, 1439-1447.	2.2	3
75	Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open, 2020, 5, e000595.	4.5	2
76	Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 610-610.	1.6	2
77	Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.. Journal of Clinical Oncology, 2017, 35, 529-529.	1.6	2
78	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).. Journal of Clinical Oncology, 2019, 37, TPS179-TPS179.	1.6	2
79	Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4108-4108.	1.6	2
80	Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. OncoTargets and Therapy, 2015, 8, 243.	2.0	1
81	Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. Investigational New Drugs, 2016, 34, 468-473.	2.6	1
82	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open, 2019, 4, e000590.	4.5	1
83	Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. Scientific Reports, 2020, 10, 17455.	3.3	1
84	A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.. Journal of Clinical Oncology, 2016, 34, TPS3632-TPS3632.	1.6	1
85	A unique ex vivo tumor model: 3D cocultured system with cancer and stromal cells including blood microvessels.. Journal of Clinical Oncology, 2020, 38, 211-211.	1.6	1
86	Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting. Dose-Response, 2021, 19, 155932582110476.	1.6	1
87	The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)â€"GI-SCREEN 2013-01-CRC sub-study.. Journal of Clinical Oncology, 2016, 34, 3573-3573.	1.6	1
88	Prognostic factors of trastuzumab-based chemotherapy in patients with advanced HER2 positive gastric cancer.. Journal of Clinical Oncology, 2017, 35, 41-41.	1.6	1
89	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1
90	Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''. British Journal of Cancer, 2018, 118, 1278-1279.	6.4	0

#	Article	IF	Citations
91	ASO Author Reflections: Combining Intensive Neoadjuvant Therapy with Minimally Invasive Surgery: A Promising Future Strategy for Rectal Cancer with High-Risk Features. Annals of Surgical Oncology, 2019, 26, 753-754.	1.5	0
92	Outcomes of Surgical Treatment for Patients with Anorectal Malignant Melanoma; Results of Nine Cases in a Single Institution. Journal of the Anus, Rectum and Colon, 2021, 5, 192-196.	1.1	0
93	What are the limiting factorsÂrelated to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer?. Journal of Clinical Oncology, 2012, 30, 149-149.	1.6	0
94	A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.. Journal of Clinical Oncology, 2012, 30, 643-643.	1.6	0
95	Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin.. Journal of Clinical Oncology, 2013, 31, e15105-e15105.	1.6	0
96	The efficacy of oxaliplatin-based adjuvant chemotherapy for stage IV colorectal cancer after R0 resection.. Journal of Clinical Oncology, 2014, 32, 638-638.	1.6	0
97	ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin.. Journal of Clinical Oncology, 2015, 33, 174-174.	1.6	0
98	A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).. Journal of Clinical Oncology, 2015, 33, 758-758.	1.6	0
99	Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2015, 33, 649-649.	1.6	0
100	Clinical features and outcome of advanced or metastatic gastric cancer in young adult,analysis of 97 cacses.. Journal of Clinical Oncology, 2015, 33, e15022-e15022.	1.6	0
101	Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression.. Journal of Clinical Oncology, 2015, 33, e15034-e15034.	1.6	0
102	Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 185-185.	1.6	0
103	Real-world data analysis of antiangiogenic targeted treatments in second-line following anti-EGFR antibodies and FOLFOX in first-line for patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 43-43.	1.6	0
104	Clinical usefulness of postoperative serum carcinoembryonic antigen in colorectal cancer patients with liver metastases.. Journal of Clinical Oncology, 2022, 40, 178-178.	1.6	0
105	Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3528-3528.	1.6	0